Gilead Sciences Secures New Clinical Trial Approval in China for ADC Drug Sacituzumab Govitecan in Recurrent or Advanced Endometrial Cancer
Gilead Sciences
Antiviral Drug Developer
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration has announced that the injectable Sacituzumab Govitecan submitted by Gilead Sciences has been approved again for clinical trials.
Source: CDE Official Website
The indication for this clinical trial isFor patients with recurrent or advanced endometrial cancer whose disease has progressed after receiving platinum-based chemotherapy and antibody treatment targeting programmed cell death protein 1 or its ligand 1 (PD-1/PD-L1).
In China,戈沙妥珠单抗自2022obtained the approval from the National Medical Products Administration (NMPA)Approval，For the treatment of locally advanced or metastatic triple-negative breast cancer.
Endometrial cancer ranks second among gynecological malignant tumors globally., the incidence and mortality rates are on the rise. Although early or localized endometrial cancer can be treated with surgery and patients generally have a more optimistic prognosis, for those with advanced or metastatic/recurrent endometrial cancer,The five-year survival rate is usually less than 20%.
The new round of clinical trial approval for Sacituzumab Govitecan Injection in China brings new treatment hope to patients with advanced or metastatic/recurrent endometrial cancer.
Operation｜Han Jinrui
